BTG plc: Northwestern University Adopts Y90 TARE with TheraSphere® as First-Line Treatment for HCC
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]
SOURCE BTG plc
Based on experience with 1000 patients over 15 years, the largest single-centre prospective, cohort of patients with HCC treated with Y90 glass microspheres
LONDON, December 12, 2017 /PRNewswire/ --
BTG plc (LSE: BTG), a global specialist healthcare company, today announced that following positive results of its 15-year experience between 2003 and 2017 with TheraSphere®, Northwestern University, Illinois has adopted Y90 transarterial radioembolisation (TARE) with TheraSphere® as the primary trans-arterial loco-regional therapy (LRT) for patients with hepatocellular carcinoma (HCC) limited to the liver.
(Logo: http://mma.prnewswire.com/media/513730/BTG_Logo.jpg )
HCC is considered to be the most common primary liver cancer and represents the second most common cause of cancer mortality worldwide. Northwestern University's decision to adopt TARE with TheraSphere® as a first-line transarterial LRT for patients with HCC was informed by data prospectively collected and incrementally reported, demonstrating outcomes as expected by the BCLC algorithm for stages A-D, applied as either neoadjuvant or definitive treatment. Compared with TACE, the data confirm that outpatient TARE allows for fewer treatments, better quality of life, longer time to progression and versatile application as neoadjuvant LRT combined with either resection or orthotopic liver transplantation.
"Patients are looking for treatments that are safe, efficacious, have minimal detrimental effects on their quality of life and as pain free as possible," said Dr Riad Salem, Chief, Section of Vascular & Interventional Radiology, Department of Radiology at Northwestern University and lead author of the paper "Institutional Decision to Adopt Y90 as Primary Treatment for HCC Informed by a 1,000-patient 15-year Experience" recently accepted for publication in Hepatology. "The benefit of Y90 TARE with TheraSphere® is that it meets all of these patient needs, and also enables patients to be treated as outpatients, permitting discharge on the same day, reducing the need for lengthy hospitalisations and minimising impact on daily life. We recognise the many approaches to establishing a new standard of care. In our case, we are proud of the controlled, prospective studies we completed over the last decade, each addressing a specific question, and each getting us closer to the unanimous, multidisciplinary adoption of Y90 as first-line. We are hopeful that when colleagues and peers review the study, the long-term survival outcomes, our rationale and the strength of the evidence, many will follow suit."
Peter Pattison, BTG General Manager Interventional Oncology, commented, "We are delighted that Northwestern University Hospital has chosen to adopt Y90 TARE with TheraSphere® as the first line trans-arterial LRT for patients with HCC. This first publication featuring over 1000 HCC patients treated with TheraSphere® represents a major milestone and we are proud to partner with healthcare professionals to deliver improved treatment options for patients."
Since TARE Y90 was FDA approved in 1999 and made available for clinical use in early 2000, radiation therapy has become widely available as an effective option to treat HCC. Treatment with Y90 TARE infuses TheraSphere® Y90 glass microspheres into the arteries that feed liver tumours. The microspheres deliver a targeted radiation dose to the tumour, minimising exposure to healthy tissue and can be adapted for each patient, allowing for a personalised treatment approach.
About BTG Interventional Oncolo
you should be used to it by now.. Its the usual fall before a small jump then a crash after they release a negative RNS.. As I said in the past INMO this is now a spiv stock..
If its any consolation I was suckered into buying Clinigen after Quanton pharma was sold out.. So in terms of spivs BTG still has some way to go, but I wouldn't be surprised if they catch them up soon.
personally I will be out of this when it hits my target..Which at the moment seems way off.
I think BTG should change their name to Chinese Torture Plc !!! "DOES ANYBODY KNOW WHATS GOING ON" !!!
Drip drip drip down every bl**dy day !! It's a joke especially as all the brokers are positive on the potential sales of the snake venom !!!
This is a joke !! Let's hope the news conference today ay have something positive to say !!!
I HAVE A DREAM !!!
Goodness me this is so frustrating !!!
oMG I've like many have been in this share forever 10 years based upon Varisolve !! I'm sick and tired of looking in every day to see if there's movement. NOT !! Don't get me wrong I've made shed loads based upon the speculation but I'm so bored with it and am also thinking of getting out. I raised serious concerns over the years on the main board taking money out and never ever a dividend being offered. Don't need advice like yourselves but this is so tedious !!
If I don't post again wish you all a very happy Christmas x
BTG plc: have Appointment another Non-executive Director, at least this guy has sales and marketing experience, both in the US and emerging markets, but he has no experience in Europe or Asia according to the document , which is shame, as that is where we need to start selling our products What is with BTG and it's fear of Europe and Asia ? why can't this BOD see past the USA ? it's as if they are blind to other markets .
At least this guy doe's have some experience in Sales &Marketing ,so hopefully, he will be able to pass on some valuable information to the present sales & Marketing Director, and his team of sales people. This appointment to me shows that BTG have no sales & marketing strategy, nor do they, have the knowledge to run such a department, this is bourn out by the wellstate debacle which cost BTG $55m,if this new guy can help sought out our marketing and sales dept. then he will be worth the extra cost ,but if not ,then it will more cash down the executive drain .
London, UK, 27 November 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces the appointment of Gregory Barrett as a non-executive director of the Board.
Greg has a broad range of commercial experience in the US medtech industry, with a focus on interventional medicine therapies. He is currently a non-executive director of Cutera Inc and was previously President and Chief Executive Officer of DFINE Inc, Barrx Medical Inc, and ACMI Corporation. Prior roles include leading a minimally invasive surgery division of Boston Scientific, both in US and in emerging markets. Greg has also held a series of senior sales and marketing roles at a number of companies including Baxter Healthcare and C.R. Bard.
Garry Watts, BTG's Chairman, commented: "Greg brings a strong track record to BTG, with significant US commercial and international medtech experience, which will be of great benefit to us as we continue to implement our growth plans."
There are no further details to be disclosed in relation to paragraph 9.6.13R of the Financial Conduct Authority Listing Rules.
I got into this stock originally on the prospect of their 'varicose vein' treatment. This has gone hardly anywhere, and I think that it probably won't ever do much.I have stood by and watched on as Louise Makin and her cronies milked the company of fat bonuses and share issues with zero dividend income to the shareholders.At the same time I watched the share price oscillate up and down like a disjointed yoyo. I therefore decided to sell my holdings at £7.52 yesterday and re-invest the money in the hope of getting a better return.
I may have made a mistake, but only time will tell
I too am a long term holder (although not posted in here for a while) and the recent results were strong and the market clearly likes them. I'd say the drop is to do with the JPM note reducing it's target from £7.50 to £7.30, albeit upgrading most estimates of numbers and re-iterating HOLD. Numis still think £9 and to me anything starting with a £7 is a comfortable place to be. It will require more info as the price is settling and let's see what comes out of the CMD on 7 Dec. All feeling pretty strong and well underpinned to me though...
I am afraid this is now a spiv stock in the eyes of a lot of new investors together with long standing ones like myself.
One half of the pantomime horse has gone. I myself hope the other half goes and a quick sale follows of the company to a suitor which now can add some value..
Don't get me wrong the existing board did well up until three years ago. However they were handsomely rewarded for their efforts.. Even though they managed to offload some shares before negative RNS followed.
Todays drop is interesting.. Probably a institution dumping stock or even worse some other mess up by the board.
They also work with the FDA in regards to trials, they can also accelerate drug clearance when a product has been given FDA clearance if they so wish .so I don't see any advantage from just sticking to the USA as any market as big as Europe's can not be left out of any companies growth predictions.
I would also say, most sales and marketing companies' in this area of expertise all ready offer a good service to US companies' ,and work hard to sell their products under licence right across Europe ,and they make excellent profits, for them self's and the companies they work with .
Personally I can't see any reason why BTG couldn't employ a UK and European sales team of their own ,while at the same time, taking on other licenced products to sell along side their own, A.G.Y can do it very successfully, as can VEC and smiths, plus, many other big pharmaceutical companies, and remember, licencing good products can also bring big rewards, not every company is sued for bad workmanship, or for breaking their contract ,smiths for instance have been doing it for years, and do very well out of it.
In your post you suggest, that maybe some body in the USA is looking BTG over ,with a view to taking us over ,if that was the case,then wouldn't our C.F.O know some thing about such a take over ? if that was the case then why is he stepping down, wouldn't he not remain in place until such a deal was concluded, just in case you were not aware : BTG plc announces that after 10 years as Chief Financial Officer (CFO) at BTG, Rolf Soderstrom is to step down as an Executive Director of the Company. The Board intends to appoint Duncan Kennedy to succeed Rolf as CFO on 1 January 2018. Rolf will remain with the Company until completion of a smooth handover to Duncan, which is expected to be concluded by 31 March 2018.full story see link
Personally I have no idea why the board are not interested in Europe or the rest of the world ,all I do know, is Europe is missing out on our technology ,and we are missing out on the profit we could be generating there ,and it's also holding back growth.
Obviously this is just my view, but I would be interested to hear what other shareholders views are regarding this subject .
Product licences around the world are not really helped by USA ones. Actually UK ones can be better! Europe is a very expensive market as in sales it is lots of individual markets all different to operate in. We like tablets, the Italians injections the French suppositories. And remember the USA sales are supported by an in house sales team. If you use distributors you give away most of the local profit and have to make money on manufacturing and royalty type profits which can be much smaller.
With all the clear cost of the USA presence - hence the lost legal case because even there they had to stop promoting the less important product and suffered the damages they are probably right to concentrate there. I also suspect that is where they see the eventual sale of the business.
Remember the owners are fund managers who will be pushing for an exit soon. Who will buy? Anyone who wants to develop a strong presence in the USA who is not there already for which BTG is a strong base or any US company wanting to expand their presence.
Either way the lack of a Europe or ROW strategy suggests to me they are near to sale ......
Looking through this set of results,they appear to be very good ,as predicted sales in the US are up .Product sales are 17% and were driven by Interventional Oncology, Interventional Vascular and Pharmaceutical there was also Strong growth in the adjusted operating profit, but operating profit declined by 36% this was due to the fine we incurred (£53.5m) following the final court ruling regarding the Wellstat litigation, how ever ,the company Continued to deliver strong cash generation, with free cash flow up 35% ,had it not been for the wellstat debacle ,I believe, the company is moving in the right direction .
The only thing I'm not sure about is the move to drop G.B.P for reporting audits, and sales figures in the future, the board in their wisdom have decided to use the U.S.D instead, this I fear could be the beginning of a major shift regarding ,BTG intention of moving much of their production act to the USA , It could also mean, BTG, intend to concentrate on the USA market only , and would explain why the company is so reluctance to gain E.U clearance for some of our other drugs/procedures such as Varithena®.
To me, this company in the past has not taken advantage of Europe ,Australia, Asia ,south America and Africa,in fact, Geographical analysis show that BTG only sold £21.09m of goods in to Europe ,that's less than £1M to each of the European countries that's shocking , and they only sold £7m of goods to the rest of the world ,now that's unbelievable for a company like BTG, but in the USA,BTG sold £341.03m in Six months, now just think to your self's just how much could our turn over figure have been, had we been trading with the rest of the world in the same way, as we are in the USA?and how much would BTG be worth now had we engaged the rest of the world ?.
Can any body out there tell me why we ignore the rest of the world ? and just concentrate on north America, especially as we all know most countries will automatically offer clearance to a drug or mechanical device that has all ready received FDA clearance? Or they fast track it, so why do BTG disregard 70% of the worlds markets that are open to them ?
While your thinking about that, its good to see BTG have maintained their mark up at about 69% and have not reduced it in order to gain market share.
Results tomorrow. Looks like it will be bad news although nothing that we don't already know. May be dropping back to the £5 mark before recovering next year, unless more skeletons fall out of the cupboard!
Apart from their usual ineptness of late something else might be going on.
How about someone looking at possibly taking them over.. Hence why the price has been knocked back from 7.78.
The bidder may have approached them indicating they might be interested in making an offer.
So don't be surprised if we get an Rns saying a possible offer may materialise after due diligence is carried out.. I would imagine that the bidder will want to make a better job of their due diligence and be more thorough than BTG have ever been.
My guess is that this will eventually go for about 15% up from where we are now.
Third-quarter Multiple Sclerosis (MS) sales grew 15.7% to 495 million, driven by Aubagio® performance in the U.S. and Europe. Year-to-date MS sales increased 24.8% to 1,540 million.
Third-quarter Aubagio® sales increased 19.2% to 382 million driven by the U.S. (up 20.9% to 274 million). In Europe sales of Aubagio were up 16.0% to 86 million. Year-to-date Aubagio® sales increased 26.9% to 1,178 million.
In the third quarter Lemtrada® sales were up 5.4% to 113 million, including 60 million in the U.S. (stable) and 40 million in Europe (up 10.8%). Year-to-date Lemtrada® sales increased 18.5% to 362 million.
Great report. Good explanation as to why share price has recently picked up. I am amazed how thin the free float of shares is after you ignore the institutions and insider owners. Means we all need to sell before they do!!! And I guess it means they all want an offer for the company at some time at the right price.
Researchers from the UCL Cancer Institute and BTG (LON:BTG) have started the first clinical trial of microscopic beads loaded with a targeted, cancer-fighting drug for patients with primary liver cancer or metastatic colorectal cancer.
The trial is designed to evaluate the experimental therapys ability to deliver a precise amount of vandetanib directly to the arteries feeding a liver tumor using a radiopaque bead which can be seen on CT scans.
The incidence and mortality rates for primary liver cancer continue to climb and it is vital that we explore new treatment approaches, primary investigator Ricky Sharma said in prepared remarks.
For full article follow link below
I have been trying to get some info on the new company we have acquired ,( Roxwood ) to see what it does, and to see what it's turn over and profits are ,but unfortunately they are not divulged .
The company is partly owned by Volcano Capital investments, they specialise in health care companies, and include venture capital, public equities and debt. They also provide funding and operational expertise see link below . www.volcanocap.com/secondary.asp?pageID=1
As BTG have not given any clues as to Roxwoods turn over or profit margins, we can not see if this bolt on is a good buy or not see link below ,however, as Dave 297 says it will fit in well with our other products. and as for increasing sales act through our own sales force ,well I would have thought that would depend, on whether or not we can get out of the Abbott sales and distribution agreement that Roxwood signed with them on the 17 July this year .
As for todays up date, well it seems to be inline with their forecast .I would have liked to have seen in that up date BTG had made an application to the European medical council for clearance of Varithena® in Europe, as varicose vain surgery, is now growing rapidly in the UK and Europe according to the latest research see link
Apart from arrogant behaviour of the ceo and the finance director. What is BTG going to do to add to shareholder value during the next six months. Apart from collecting share options and honours handed out by the serfs that hold this good old British stock (Hopefully soon to be owned by an overseas competitor)
"BTG shares still good value despite court case blow, says Numis
A Delaware court has ruled against drug developer BTG (BTG) over a distribution agreement but Numis said there would be little financial impact and the shares remained good value.
Analyst Paul Cuddon retained his buy recommendation and target price of 900p on the shares, which were flat at 667p yesterday.
A Delaware court ruled against BTG in relation to a breach of a distribution agreement signed with WellStat Therapeutics in 2011 concerning the commercialisation of chemotherapy drug Vistoguard, which generated £3.5 million of sales in 2017.
The disagreement lies in the effort BTG made in deploying a large enough salesforce to sell the drug.
We would expect BTG to appeal the ruling or otherwise seek to reduce the bill or return the rights, said Cuddon.
The $55.8 million settlement equates to 20% of BTGs net cash resources and makes little difference to forecasts or valuation. The shares trade on less than 19x ex-cash price/earnings and remain good value in our view.
At the time of writing the shares were trading down 0.9%, or 6p, at 661p."
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.